Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
This includes frequently reported gene fusions such as CCDC6/RET (PTC1), PRKAR1A/RET (PTC2) and ETV6/NTRK3 , and gene fusions that are less common in thyroid cancer (TPM3/NTRK1, EML4/ALK and EML4/NTRK3).
|
30668525 |
2019 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several drugs targeting RET have been approved by the FDA for the treatment of cancer: (i) cabozantinib and vandetanib for medullary thyroid carcinomas and (ii) lenvatinib and sorafenib for differentiated thyroid cancers.
|
29284153 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.
|
29515777 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated whether the oncogenic RET mutants RET2A (C634R) and RET2B (M918T) were regulated by LRIG1, and the possible effects of LRIG1 expression in thyroid cancer were investigated in three different clinical cohorts and in a RET2B-driven mouse model of MTC.
|
29436694 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been observed in patients with RET-rearranged lung cancers or RET-mutant thyroid cancers.
|
29134959 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results confirm that PATZ1 downregulation has a critical role in thyroid carcinogenesis, showing that it cooperates with RET/PTC1 in thyroid cancer progression.
|
29584698 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
<i>In vivo</i>, BLU-667 potently inhibited growth of NSCLC and thyroid cancer xenografts driven by various <i>RET</i> mutations and fusions without inhibiting VEGFR2.
|
29657135 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
While RET TK inhibitors (TKIs) are used to treat thyroid cancer and are in clinical trials for RET fusion-positive non-small cell lung cancer, the impact of mutations in the RET kinase domain on drug sensitivity is largely uncharacterized.
|
29908090 |
2018 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
|
28911727 |
2017 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima.
|
28351223 |
2017 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
To assess the therapeutic potential of AL3810 in treating thyroid cancer involving RET gene fusion, we showed that AL3810 (1-10 μmol/L) dose-dependently inhibited the proliferation of RET-driven Baf3 cell line Baf3-CCDC6-RET, and the auto-phosphorylation of RET in these cells.
|
28795691 |
2017 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.
|
27555670 |
2016 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the best tagging SNPs from our previous PTC study and additionally included SNPs in or near FOXE1 and NKX2-1 genes, known susceptibility loci for thyroid cancer.
|
27207655 |
2016 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
|
27712045 |
2016 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants.
|
26652860 |
2016 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
RET, BRAF and other protein kinases have been identified as major molecular players in thyroid cancer.
|
27058903 |
2016 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In present result, RET rs1799939, rs1800858 and rs74799832 polymorphisms might be the risk factors for TC.
|
26191299 |
2015 |
Malignant neoplasm of thyroid
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we firstly find CNTN1 is a new gene which can be regulated by RET/PTC3 (Ret proto-oncogene and Ret-activating protein ELE1) rearrangement gene and the protein level of CNTN1 is increasing in thyroid cancer.
|
26722434 |
2015 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Twenty-four (27%) of 89 patients were diagnosed with thyroid cancer (50% papillary thyroid carcinoma [PTC], 50% follicular variant of papillary thyroid carcinoma [FVPTC]).
|
25627462 |
2015 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In particular, activating mutations of BRAF, RET or RAS genes are known to be specifically associated with TC initiation, progression and outcome.
|
25862858 |
2015 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer.
|
25789503 |
2015 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data indicate that RAF-1 is important for the survival of TPC-1 cells independently of the classical MEK1/2-ERK activation, offering new perspectives on RET/PTC signaling and for the therapy of thyroid cancers.
|
26265449 |
2015 |
Malignant neoplasm of thyroid
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Possible Impact of RET Polymorphism and Its Haplotypic Association Modulates the Susceptibility to Thyroid Cancer.
|
25736215 |
2015 |
Malignant neoplasm of thyroid
|
0.400 |
Biomarker
|
disease |
BEFREE |
We sought to evaluate the prognostic value of the three most common genetic mutations (BRAF, RAS, and RET) in patients with thyroid cancer.
|
25244593 |
2015 |